August 8, 2018 7:28pm

RGNX closed down -$0.25 to $70.55 with an aftermarket downside of -$0.45 or -0.64% - SELL

After reporting Q2 net income of $10.6 M or a profit of $0.30 per share; earnings, adjusted for non-recurring gains, were $0.15 per share.

RGNX intends to offer and sell, subject to market conditions, $175 M of its common stock in an underwritten public offering.

As usual, “the offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or the actual size or terms of the offering. In addition, REGENXBIO intends to grant the underwriters a 30-day option to purchase up to an additional 15% of the number of common shares sold in connection with the offering.’


Morgan Stanley, BofA Merrill Lynch and Barclays are acting as joint book-running managers. Raymond James is acting as co-manager of the offering.


A few stats:

  • Q2 ended with a cash position of $306.3 M and a runway until 2021,
  • Shares outstanding: 31.94 M with a float of 20.49 M shares.
  • A 52 week high of $85.10 and a low of $19.45,
  • A 53 week change: 240.38%

A good reason for an offering, RGNX shares have more than doubled since the beginning of the year. The stock has nearly quadrupled in the last 12 months.